Posted On: 12/14/2015 1:24:41 PM
Post# of 193
Valeant ($VRX) on Defensive, Fights Back Critics
You would think that a stock-price collapse of more than 60 percent might convince Valeant to change its ways.
But as it approaches a high-pressure investor meeting on Wednesday, where frustrated shareholders expect a detailed plan to restore profit growth, the Canadian specialty pharmaceutical firm remains defiant about a core part of its business -- its increasingly controversial model of buying inexpensive drugs and jacking up their prices, while spending little on its own research and development.
Continue reading http://www.bloomberg.com/gadfly/articles/2015...-defensive
You would think that a stock-price collapse of more than 60 percent might convince Valeant to change its ways.
But as it approaches a high-pressure investor meeting on Wednesday, where frustrated shareholders expect a detailed plan to restore profit growth, the Canadian specialty pharmaceutical firm remains defiant about a core part of its business -- its increasingly controversial model of buying inexpensive drugs and jacking up their prices, while spending little on its own research and development.
Continue reading http://www.bloomberg.com/gadfly/articles/2015...-defensive
(0)
(0)
